Whole-exome sequencing and targeted copy number analysis in primary ciliary dyskinesia by Marshall, C.R. et al.
INVESTIGATION
Whole-Exome Sequencing and Targeted Copy
Number Analysis in Primary Ciliary Dyskinesia
Christian R. Marshall,*,† Stephen W. Scherer,†,‡ Maimoona A. Zariwala,§ Lynette Lau,* Tara A. Paton,†
Tracy Stockley,* Rebekah K. Jobling,** Peter N. Ray,* Michael R. Knowles,†† FORGE Canada
Consortium, David A. Hall,‡‡,§§,1,2 Sharon D. Dell,***,†††,‡‡‡,1,2 and Raymond H. Kim**,§§,‡‡‡,1,2
*Department of Pediatric Laboratory Medicine, †The Centre for Applied Genomics, Genetics and Genome Biology,
**Division of Clinical and Metabolic Genetics, ***Child Health Evaluative Sciences, and †††Division of Respiratory
Medicine, The Hospital for Sick Children, Toronto, ON, M5G 1X8, Canada, ‡Department of Molecular Genetics and the
McLaughlin Centre, University of Toronto, Toronto, ON, Canada, §Department of Pathology and Laboratory Medicine
and ††Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599,
‡‡Division of Respirology, St. Michael’s Hospital, Toronto, ON, M5B 1W8, Canada, and §§Department of Medicine and
‡‡‡Department of Pediatrics, University of Toronto, Toronto, ON, Canada
ABSTRACT Primary ciliary dyskinesia (PCD) is an autosomal-recessive disorder resulting from loss of normal ciliary
function. Symptoms include neonatal respiratory distress, chronic sinusitis, bronchiectasis, situs inversus, and infertility.
Clinical features may be subtle and highly variable, making the diagnosis of PCD challenging. The diagnosis can be
confirmed with ciliary ultrastructure analysis and/or molecular genetic testing of 32 PCD-associated genes. However,
becauseof thisgeneticheterogeneity,comprehensivemoleculargenetic testing isnotconsideredthestandardofcare,
andthemostefficientmolecularapproachhasyet tobeelucidated.Here,weproposeacost-effectiveandtime-efficient
molecular genetic algorithm to solve cases of PCD.We conducted targeted copy number variation (CNV) analysis
and/or whole-exome sequencing on 20 families (22 patients) from a subset of 45 families (52 patients) with a clinical
diagnosisofPCDwhodidnothaveamoleculargeneticdiagnosisafterSangersequencingof12PCD-associatedgenes.
This combined molecular genetic approach led to the identification of 4 of 20 (20%) families with clinically significant
CNVs and 7 of 20 (35%) families with biallelic pathogenic mutations in recently identified PCD genes, resulting in an
increased molecular genetic diagnostic rate of 55% (11/20). In patients with a clinical diagnosis of PCD, whole-exome










Primary ciliary dyskinesia (PCD, MIM#244400) is a genetically het-
erogeneous, autosomal-recessive motile ciliopathy. Clinical manifestations
include situs inversus, neonatal respiratory distress, progressive bron-
chiectasis, and respiratory failure in young adulthood. To date, there
are 32 genes associated with PCD that account for a genetic diag-
nosis in approximately 65% of all patients with PCD (Kurkowiak
et al. 2015).
The clinical diagnosis of PCD is challenging and relies on patient
features and diagnostic investigations. These include diagnostic
imaging, nasal nitric oxide levels, cilia beat frequency, and ciliary
ultrastructure analysis by electron microscopy (EM) (Leigh et al.
2011). Historically, a diagnosis of PCD has relied on the findings of
a classic ciliary ultrastructural defect on EM (Barbato et al. 2009). EM
of normal motile cilia consist of nine peripheral microtubule doublets
encircling a central microtubular complex supported by microtubular-
associated proteins such as outer and inner dynein arms (ODA, IDA,
respectively), radial spokes, and nexin links (Knowles et al. 2013a).
A molecular genetic diagnosis of PCD can be established through
the identification of biallelic loss-of-function mutations in a PCD-
associated gene. Mutations in certain PCD genes result in ciliary
Copyright © 2015 Marshall et al.
doi: 10.1534/g3.115.019851
Manuscript received April 30, 2015; accepted for publication June 19, 2015;
published Early Online July 2, 2015.
This is an open-access article distributed under the terms of the Creative
Commons Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited.
Supporting information is available online at www.g3journal.org/lookup/suppl/
doi:10.1534/g3.115.019851/-/DC1
All work was conducted at Hospital for Sick Children and St Michael’s Hospital,
Toronto, Ontario, Canada.
1These authors contributed equally to this work.
2Corresponding authors: Division of Metabolic and Clinical Genetics, The Hospital
for Sick Children, 555 University Ave, Toronto, ON, M5G 1X8. E-mail: raymond.
kim@utoronto.ca; Division of Respiratory Medicine, Room 4543, The Hospital for
Sick Children, 555 University Ave, Toronto, ON, M5G 1X8. E-mail: sharon.dell@
sickkids.ca; and Division of Respirology, St Michael’s Hospital, 30 Bond Street,
Toronto, ON, M5B 1W8. E-mail: hallda@smh.ca
Volume 5 | August 2015 | 1775
dysfunction and can give a specific ultrastructural defect on EM
(Knowles et al. 2013a). ODA defects are the ultrastructural defect
observed most frequently in PCD and are associated with muta-
tions in DNAH5, DNAI1, DNAI2, DNAL1, TXNDC3, CCDC114,
and ARMC4 (Lobo et al. 2015). Defects in both ODA and IDA
are seen in patients carrying mutations in LRRC50/DNAAF1, KTU/
DNAAF2, DNAAF3, CCDC103, HEATR2, LRRC6, ZMYND10,
DYX1C1, C21orf59, and SPAG1. IDA defects with microtubular
disorganization are seen with mutations in CCDC39 and CCDC40.
Central microtubular abnormalities are observed with mutations in
RSPH1, RSPH4A, and RSPH9. Patients with mutations in CCNO
and MCIDAS have ciliary aplasia/oligoplasia and a marked reduc-
tion of cilia (oligocilia) due to a deficiency in ciliogenesis rather
than motility. In addition, patients with mutations in DNAH11,
HYDIN, CCDC164/DRC1, and CCDC65/DRC2 do not have obvi-
ous ciliary ultrastructural defects and would be not be diagnosed
with PCD on the basis of biopsy EM alone. We have shown pre-
viously that molecular genetic analysis can complement ciliary
ultrastructure analysis and increase the overall diagnostic yield
from 57% (28/49) to 69% (36/52) (Kim et al. 2014). However,
the molecular genetics of PCD are complex and not considered
routine in the diagnostic evaluation of patients (Barbato et al.
2009; Bush and Hogg 2012). Modern advances in molecular ge-
netic technologies may overcome some of these perceived limita-
tions in a cost-effective manner.
In genetically heterogeneous diseases such as PCD, selecting the
appropriate gene and technique for molecular analysis is often
difficult. Sanger sequencing is available for many, but not all, of the
32 PCD-associated genes. A step-wise approach by prioritizing
genes based on ciliary ultrastructure and prevalence of mutations
could be conducted using Sanger sequencing (Bush and Hogg
2012; Kim et al. 2014). However, as the number of genes tested
increase, Sanger sequencing can become costly and time-consuming.
In PCD, many new loci are being discovered on an ongoing basis,
quickly out-dating existing available panels. Moreover, newly discov-
ered loci account for a minority of patients with PCD (Knowles et al.
2013a), decreasing the diagnostic value for each gene added to a con-
ventional panel.
Intron-exon level copy number variations (CNVs) are seen in up
to 10.8% of autosomal-recessive Mendelian disorders and are not
detectable by Sanger sequencing (Aradhya et al. 2012). Deletions in
SPAG1, ARMC4, DYX1C1, LRRC50, and ZYMD10 have been ob-
served in isolated PCD cohorts (Loges et al. 2009; Blanchon et al.
2012; Hjeij et al. 2013; Knowles et al. 2013b; Tarkar et al. 2013;
Zariwala et al. 2013), suggesting CNV analysis should be used in
the molecular evaluation of patients with PCD. However, the preva-
lence and clinical significance of CNVs in other PCD-associated genes
have not been examined.
Whole-exome sequencing (WES) has been used extensively for
gene discovery and is beginning to be used in clinical practice in the
diagnosis of genetically heterogeneous diseases (Neveling et al. 2013).
The advantages of WES include providing a genomic approach in
molecular genetic diagnoses through the analysis of all potential caus-
ative genes, including recently discovered genes not available on clin-
ical gene panels (Boycott et al. 2015). Furthermore, this strategy allows
for more complete interpretation of variants of uncertain significance
(VUS), and can guide further molecular genetic analyses such as
targeted CNV analysis. Because of ongoing gene discovery in genet-
ically heterogeneous diseases such as PCD, WES may be a more cost-
effective technique (Lucas et al. 2014; Kurkowiak et al. 2015). Here, we
describe the complementary role of WES and targeted CNV analysis




Between the period of August 2011 and December 2012, Sanger
sequencing of 12 PCD genes was clinically available and conducted on
45 families with a clinical diagnosis of PCD (Kim et al. 2014). A total
of 19 families (42%) were found to have biallelic pathogenic mutations
in these 12 PCD genes and thus confirmed a molecular diagnosis.
Pathogenic mutations were defined as mutations previously docu-
mented in patients with PCD; or nonsense, frameshift and splice-site
mutations resulting in loss-of-function. Four families were solved in
other research studies (Supporting Information, Table S1) leaving 22
families unsolved. Twenty families consented to have CNV analysis
and/or WES. This study was approved by the Research Ethics Boards
of the Hospital for Sick Children and St Michael’s Hospital. Study
subjects provided written consent and/or assent where appropriate.
Molecular genetic analysis algorithm
A molecular genetic analysis algorithm was developed to maximize
previous molecular genetic data and minimize time and cost. In-
dividuals were divided into three categories depending on the in-
formation from previous Sanger sequencing and WES performed in
this study (Figure 1). For the individuals who harbored single patho-
genic mutations after Sanger sequencing, targeted CNV analysis of the
putative causative gene was conducted to ascertain the second allele
(category A). Individuals with no pathogenic mutations after Sanger
sequencing underwent WES to analyze the remaining 20 genes not
covered by Sanger sequencing (category B). WES-sequenced individ-
uals who were not found to have any pathogenic mutations in a PCD
gene, further analysis of missense variants occurring at a minor allele
frequency of ,1% was conducted. Rare missense variants were con-
sidered to be contributory if predicted to be pathogenic, disease caus-
ing or damaging by in silico prediction programs (MutationTaster,
PolyPhen-2, SIFT). These individuals underwent further targeted
CNV analysis on the suspected PCD gene (category C).
Targeted CNV analysis
The selected technique for targeted CNV analysis was based on
previously reported intron2exon CNVs in the literature. Exon 7 deletions
in DYX1C1 have been documented in other PCD cohorts (Tarkar et al.
2013), and a custom TaqMan copy number assay was designed to detect
this specific CNV (File S1). Reported deletions of exon 62 of DNAH5
(Berg et al. 2011) along with the remaining 78 exons were assayed
using a commercially available, high-density gene-centric array com-
parative genomic hybridization (CGH; Prevention Genetics, Marshfield,
WI). Similarly for DNAH11, where intron2exon level CNVs have not
been reported, CGH was used to assay all 82 exons.
WES and validation
WES was completed with the Illumina Hisequation 2500 platform at
The Centre for Applied Genomics (TCAG) at the Hospital for Sick
Children following whole-exome capture with the Agilent SureSelectXT
Human All Exon V4 capture kit. Sequence reads were aligned to
the reference human genome (hg19) with Burrows-Wheelchair
Aligner 0.5.9. MarkDuplicates (Picard tools, version 1.79; http://
broadinstitute.github.io/picard/) was used to remove any duplicate
paired-end reads. Duplicate-free alignments were refined using base
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space local realignment and quality score recalibration using GATK
1.128. Mean depth of coverage was 138X (range 1002168X) with all
cases having .95% of targeted bases sequenced to a depth of greater
than 20X.
Single-nucleotide variants (SNVs) and insertion/deletions (indels)
were called with default parameter in GATK 1.1.28. SNVs and indels
were annotated using SNPEff (http://snpeff.sourceforge.net/) and
ANNOVAR and filtered to differentiate novel variants from known
polymorphisms by screening against public single nucleotide poly-
morphism databases (dbSNP, http://www.ncbi.nlm.nih.gov/projects/
SNP/; 1000 genomes, www.1000genomes.org; NHLBI Exome Se-
quencing Project (ESP) Exome Variant Server http://evs.gs.washington.
edu/EVS/) and our own internal database consisting of 283 exomes
analyzed in the same manner at TCAG. Novel SNVs also were
annotated with SIFT, PolyPhen-2, and MutationTaster to assess
the putative variant effect on the proteins. SNVs were prioritized
based on loss of function mutations (nonsense, frameshift, splice
sites) and damaging missense mutations that fit an autosomal re-
cessive disease model.
An in silico gene panel was created by filtered analysis of WES
data. WES data were reanalyzed with the publication of new PCD
genes and the in silico panel expanded in real-time. At the time of
manuscript submission, 32 genes were analyzed for variants (DNAH5,
DNAI1, CCDC39, CCDC40, DNAI2, DNAH11, RSPH9, RSPH4A,
KTU/DNAAF2, LRRC50/DNAAF1, TXNDC3/NME8, DNAL1, DNAAF3,
CCDC103, HEATR2, HYDIN, LRRC6, CCDC114, CCDC164/DRC1,
ARMC4, DYX1C1, ZMYND10, CCDC65/DRC2, RSPH1, OFD1, RPGR,
C21orf59, SPAG1, DNAH8, CCDC151, MCIDAS, and CCNO). WES
coverage of these genes was adequate with .98% of targeted bases
sequenced and 92.08% (616/669) of exons having a mean coverage
of .20X. Confirmation of variants was conducted on probands and
available family members using standard Sanger sequencing methods
in a CLIA-CAP diagnostic laboratory and genetic counseling was
provided based on these results (Table S2).
RESULTS
Four individuals from three families harbored one pathogenic mu-
tation after Sanger sequencing (category A). Two families (111, 113)
each harbored two different nonsense mutations in DNAH5 and CNV
analysis of DNAH5 was conducted using array CGH to ascertain the
second allele. Two clinically significant CNVs in DNAH5 were found
and likely causative second allele, corresponding to the ODA defect
observed on ciliary EM (Table 1). The third family harbored a pre-
viously reported nonsense mutation in DNAH11, c.8698C . T
(p.R2900) (Lucas et al. 2012). However, DNAH11 CNV analysis with
array CGH did not detect a CNV and this case remained unsolved.
A total of 18 individuals from 17 families who did not have any
pathogenic mutations detected on initial Sanger sequencing (category
B and C) underwent WES. Seven category B families were solved by
WES alone where two pathogenic variants were found in one of the
additional 20 PCD genes not analyzed by Sanger sequencing (Table 1).
Molecular genetic results were congruent with ultrastructural analysis
when available. For those cases with available family members for
segregation analysis, phase was determined to be trans.
WES on individual 46 revealed a splice site (c.13680-1G . T) and
frameshift mutation, c.4866del (p.P1623Qfs20) in HYDIN. Because
of the presence of a pseudogene on chromosome 1 (HYDIN2), further
characterization of both variants was conducted using Sanger se-
quencing (Olbrich et al. 2012) (File S1 and Figure S1). Primers map-
ping exclusively to HYDIN on chromosome 16 were designed (Table
S2) which further resolved the next generation data from WES. The
frameshift was found to be homozygous, and likely the causative allele.
The splice site variant was heterozygous, but its pathogenicity is un-
certain. Determination of segregation would help further resolve these
variants, however, family members were not available. Ciliary biopsy
of this individual was normal, as seen in other individuals with
HYDIN mutations, further supporting the pathogenicity of the frame-
shift variant (Olbrich et al. 2012).
Individuals who did not have biallelic pathogenic mutations after
WES were reanalyzed for rare missense variants of uncertain
significance in the 32 known PCD genes. Five individuals from five
families were found to harbor such VUS.
Individual 44 was found to have a homozygous missense c.1555G
. C (p.A519P) variant in DNAAF3 (Table 2) on WES, which was not
reported in other PCD patients nor present in our control databases.
This transversion resulted in an amino acid change which is predicted
to be tolerated by SIFT and MutationTaster, and only probably dam-
aging by Polyphen-2. DNAAF3 mutations are associated with ODA +
IDA defects, not seen in this patient. We concluded this variant was
not likely contributing to this patient’s PCD phenotype and this case
remained unsolved.
Figure 1 Molecular genetic analysis algorithm: study design and
diagnostic yield per technology in patients with a clinical diagnosis
of primary ciliary dyskinesia (PCD), defined as a ciliary ultrastructure
defect and/or clinical features with low nasal nitric oxide (Kim et al.
2014). Sanger sequencing of 12 PCD genes provided a molecular di-
agnosis in 19 of 45 families. Of the 26 families who remained un-
solved, 20 underwent targeted copy number variation (CNV) analysis
and/or whole-exome sequencing (WES). Category A families had sin-
gle pathogenic mutations in PCD genes after Sanger sequencing and
underwent targeted CNV analysis alone to ascertain the second allele.
Category B families had no pathogenic mutations after Sanger se-
quencing and underwent WES. Category C families had rare variants
of uncertain significance after WES and underwent further targeted
CNV analysis to ascertain the second allele. Four families had clinically
significant CNVs and seven families were solved with WES alone giv-
ing an overall solved rate of 55% (11/20). These 11 families when taken
together with 19 families solved through Sanger sequencing, and 4
families solved in other research studies, resulted in a solved rate of
76% (34/45).
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The four other individuals were found to have rare missense VUS
predicted to be damaging, disease-causing, or deleterious by at least
one of the in silico prediction programs, MutationTaster, PolyPhen-2
and SIFT. These individuals underwent targeted CNV analysis to
ascertain a second hit (category C, Figure 1).
Individual 9 was initially found to have a single variant in DNAH5
(c.3890A. G; p.D1297G) that was predicted to be disease-causing by
Poly-Phen, SIFT, and MutationTaster and ciliary ultrastructure was
interpreted as ODA (Kim et al. 2014). However, array CGH analysis
of all exons of DNAH5 did not yield a second allele, prompting further
review of WES data. In addition to the rare variant in DNAH5, a single
rare missense variant in DYX1C1 (c.988C . T; p.R330W) was found
in WES data. This variant was not observed in control populations and
was also predicted to be disease causing by SIFT and MutationTaster.
Targeted CNV analysis by TaqMan copy number assay of a previously
reported exon 7 deletion in DYX1C1 was conducted and was found
in this individual (Tarkar et al. 2013). Subsequent segregation anal-
ysis confirmed trans orientation of the rare missense variant and
deletion. This prompted further pathologic review and revision of
the initial ciliary EM to ODA + IDA consistent with other DYX1C1
families (Table 2) (Tarkar et al. 2013), suggesting this is the causative
gene in this family.
Individual 21 was found to have a rare missense VUS (c.10285C.
A) in DNAH11 on initial Sanger sequencing and WES confirmed this
VUS. MutationTaster, PolyPhen-2 and SIFT algorithms predict the
p.R3429S change to be deleterious, probably damaging and damaging
respectively. Additionally, this is a highly conserved amino-acid resi-
due residing in the conserved Helix 2 domain (Schwabe et al. 2008).
Array CGH analysis on DNAH11 was conducted and demonstrated
a 32.29-kb duplication spanning exons 7214 and is likely the causa-
tive second allele in this individual (Table 2).
Individual 51 was found to have two previously unreported
homozygous missense variants in DNAH11, which also were detected
through WES. One variant, c.10286G . T (p.R3429L) involves the
same highly conserved amino-acid residue in the Helix 2 domain ob-
served in individual 21. The other variant, c.2750A . T (p.E917V)
also was predicted to be possibly damaging by Polyphen-2, deleterious
by SIFT, and deleterious by MutationTaster. Subsequent array CGH
of DNAH11 analysis did not reveal a deletion or duplication and this
case remained unsolved (Table 2).
Patient 38 was heterozygous in exon 82 of the DNAH11 gene for
an undocumented missense variant defined as c.13366C. T and pre-
dicted to result in p.R4456C substitution. The SIFT and PolyPhen-2
protein function algorithms predicts this change to be tolerated
and benign, whereas the MutationTaster program indicates that this
c.13366C . T variant is deleterious. However, DNAH11 array CGH
did not yield a second allele de-prioritizing this variant leaving this
case unsolved (Table 2).
Through Sanger sequencing of the first 12 PCD genes, we found
that five individuals who had a clinical diagnosis of PCD did not
harbor a disease-causing mutation in a known PCD gene, nor did we
find, using WES, a pathogenic mutation or rare missense VUS in any
of the known PCD genes (Table S3). We suspect these patients either
have a mutation not detectable by either technique or a novel PCD
locus.
Overall, the combination of targeted CNV and WES analysis
allowed for a molecular diagnosis in 55% of our unsolved families
(11/20). Clinically significant CNVs were detected in 8.8% (4/45) of our
total patient population, which is consistent with other autosomal-
recessive disorders (Aradhya et al. 2012). Of the 45 families, Sanger
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CNV analysis with WES solved an additional 11, yielding an overall
diagnostic rate of 30/45 (67%). Four further families were enrolled in
other studies, such that in our cohort, 34/45 (76%) had a molecular
diagnosis of PCD. As all variants detected by Sanger sequencing
were covered in our WES data, if our molecular genetic approach
was modified to WES followed by targeted CNV analysis, the overall
diagnostic rate would approach 76%.
DISCUSSION
In genetically heterogeneous diseases such as PCD, a step-wise molec-
ular genetic approach has been proposed based on ciliary ultrastruc-
ture and the prevalence of certain mutations. If genes are assayed in
a cost-efficient, step-wise tiered fashion, only one gene may be assayed
at one time, taking up to 426 months to complete, costing up to
$12,000 USD. In addition, expert EM ciliary ultrastructure analysis
may not be available to guide such tiered analysis. Newly developed
next-generation sequencing (NGS) targeted panels are less costly, at
$19002$4200 USD, but do not include all 32 PCD genes (Prevention
Genetics; Ambry Genetics, Aliso Viejo, CA; Center for Genomics and
Transcriptomics, Tübingen, Germany). However, unlike tiered Sanger
sequencing, NGS concurrently assays all genes. If a patient had pre-
vious genetic testing, these genes would be unnecessarily retested.
Furthermore CNV data from NGS is unreliable and not possible with
Sanger sequencing.
Here, we describe the utility of filtered WES data and targeted
CNV analysis to circumvent the limitations of targeted Sanger and
NGS panel sequencing in PCD. Because of the cost-efficiency of WES
($22$5000 USD) (Neveling et al. 2013), we propose that WES could
be conducted as a first-line molecular diagnostic test through the
analysis of an in silico gene panel, followed by targeted CNV analysis.
In addition to providing a definitive molecular diagnosis when biallelic
pathogenic mutations are found, WES provides additional informa-
tion on all PCD genes and aids in the interpretation of rare missense
VUS. In the absence of convincing pathogenic mutations in all known
PCD genes, rare missense VUS could result in loss of function and
potentially be disease-causing prompting further targeted CNV anal-
ysis. CNV analysis should be targeted to the candidate PCD-associated
gene on the basis of sequencing results. CNV analysis initially could
begin with CNVs reported other PCD cohorts, followed by more
extensive full exon analysis using array CGH or multiplex ligation-
dependent probe amplification (Stuppia et al. 2012). Further studies
are required to determine if the novel CNVs reported in our cohort
are private mutations or common to other PCD patients. In addition,
as CNV algorithms from WES data improve, they may replace other
CNV analyses and provide a genome-wide CNV approach (Samarakoon
et al. 2014). If a PCD case remains unsolved after WES and targeted
CNV analysis, WES data can be further analyzed as novel PCD loci
become published expanding the in silico panel in real-time, instead
of expending further sequencing consumables. In our population, if
WES was followed by targeted CNV analysis, 76% of patients with
PCD would have had a molecular genetic diagnosis and WES should
be considered the most cost-efficient molecular genetic technique in
such genetically heterogeneous disorders.
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